Myélome

  • Accueil
  • Myélome
  • EXCALIBER-RRMM (CC-220-MM-002)

TITRE (EN) A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
PROTOCOLE ID EXCALIBER-RRMM (CC-220-MM-002)
CLINICAL TRIAL.gov ID NCT04975997
TYPE(S) DE CANCER Myélome
PHASE Phase III
TYPE D'ÉTUDE Clinique
INSTITUTION CHU DE QUEBEC – UNIVERSITE LAVAL
11 Côte du Palais
(418) 525-4444
VILLE Québec
INVESTIGATEUR(RICE) PRINCIPAL(E) Marc Lalancette
COORDONATEUR(RICE) Patricia Chabot
patricia.chabot@chudequebec.ca
418-525-4444 poste 15769
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Documented diagnosis of multiple myeloma (MM) and measurable disease
  • Received 1 to 2 prior lines of anti-myeloma therapy
  • Must have documented disease progression during or after their last anti-myeloma regimen
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
CRITÈRES D'EXCLUSION (EN)
  • Any condition that confounds the ability to interpret data from the study
  • Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis
  • Known central nervous system involvement with MM
  • Prior therapy with iberdomide

Other protocol-defined inclusion/exclusion criteria apply